A record number of attendees and meetings during BioFIT 2017
1,200 delegates from 30 countries, 2,700 one-to-one meetings,1,000 licensing opportunities, 100 exhibitors, 80 speakers. During its 6th edition, BioFIT confirmed
its position as the leading event for technology transfer, academia-industry collaborations and earlystage innovation in the field of Life Sciences. BioFIT is also becoming the marketplace for pre-seed, seed and Series A investment. BioFIT gathers big pharma, biotech start-ups and SMEs, TTOs, researchers and investors in the same place, focused on the same goals: Entail new partnerships, source innovative and competitive early-stage R&D projects, facilitate the emergence of collaborative projects and increase licensing opportunities in Life Sciences.
2,700 meetings scheduled, a 10% increase versus 2016 BioFIT 2017 was once again an unmissable event for the actors from the Life Sciences sector. In six editions BioFIT has quadrupled its number of attendees from 300 to 1,200 and has convinced every year more and more organisations to host their events.
BioFIT is the privileged moment to source early-stage innovations, to initiate collaborations between academic and industrial sectors, to get access to seed investment and to provide keys to gain insight into the trends from the sector thanks to its 4 main activities: One-to-one meetings, conferences and roundtable discussions, presentation sessions (Start-up Slams and Licensing Opportunity Presentations) and exhibition.
In addition to scheduling business meetings, the partnering platform allowed participants to offer licensing opportunities.
2017 Participants included:
Pharma, Biotech: Astellas Pharma, Basilea Pharmaceutica International, Bayer, Bayer Animal Health, Boehringer Ingelheim, Boehringer Ingelheim Animal Health, Ceva, Daiichi Sankyo, Evotec, Ferring Pharmaceuticals, GSK, Ipsen Innovation, Johnson & Johnson Innovation, Kissei America, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Laboratorios Rubio, LFB, Lilly, Merck, MSD, MSD Animal Health, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Syngulon, Takeda, TiGenix, Trianni, Vetoquinol, Virbac, Zoetis…
TTOs and Academia: Ascension, CNRS, EMBLEM, FIST, Imperial Innovations, LifeArc, Max Planck Institute, SATT Network, University of Birmingham, University of Cambridge, VIB…
Investors: Broadview Ventures, Edmond de Rothschild Investment, Fund+, High-Tech Gründerfonds, Merck Ventures, Novartis Venture Fund, Sofinnova Partners, Thiel Capital, Truffle Capital, TVM Capital…
20 start-ups selected to pitch during BioFIT amongst 70 candidates, 2 start-ups chosen as the most innovative this year
Investors and industrials need a marketplace to identify the latest early-stage innovations that they can invest in or in-license; the emerging companies and academic spin-offs need a place where they can find their potential future investors and partners. For the first time, BioFIT rewarded the two most innovative start-ups among the 20 start-ups selected by the steering committee of BioFIT 2017.
Throughout the conferences, 80 international speakers including Andrew Fried (IBM, UK), Grit Zahn (Eternygen, DE), Peter Opdam (MSD Animal Health, NL), Tony Hickson (Imperial Innovations, UK), Duncan Holmes (GlaxoSmithKline, UK), Philippe Pouletty (Truffle Capital, FR), James Peyer (Apollo Ventures, DE), Sofia Ioannidou (Edmond de Rothschild Investment Partners, FR), Sascha Berger (TVM Life Science Management, DE) and many others, discussed around the issues and the trends on accessing and financing early-stage innovation.
The plenary session dealt with “How can we overcome the shortage of bioentrepreneurs in Europe?” and gathered 300 attendees.
BioFIT’s next edition will take place on 4th and 5th December 2018, in Lille (France).
Nadège Joly | Event Communication Officer
email@example.com | +33 (0)3 28 55 90 60